



# BIONETICS

Mutagenic Evaluation of Compound FDA 73-57-Propylene Glycol Monostearate  
5/30/75

Q 24

MUTAGENIC EVALUATION OF  
COMPOUND FDA 73-57

001323393

PROPYLENE GLYCOL MONOSTEARATE

Q 24

7315 Wisconsin Avenue  
Bethesda, Maryland  
20014

LBI PROJECT #2468

MUTAGENIC EVALUATION OF  
COMPOUND FDA 73-57

001323393

PROPYLENE GLYCOL MONOSTEARATE

SUBMITTED TO

FOOD & DRUG ADMINISTRATION  
DEPARTMENT OF HEALTH, EDUCATION AND WELFARE  
ROCKVILLE, MARYLAND

SUBMITTED BY

LITTON BIONETICS, INC.  
5516 NICHOLSON LANE  
KENSINGTON, MARYLAND

MAY 30, 1975



BIONETICS

### EVALUATION SUMMARY

Compound FDA 73-57, Propylene Glycol Monostearate, did not exhibit genetic activity in any of the in vitro microbial assays employed in this evaluation.



**BIONETICS**

DATE: May 30, 1975

SPONSOR: Food and Drug Administration, Contract Number 223-74-2104

SUBJECT: Evaluation of Test Compound 001323393, Propylene Glycol Monostearate  
FDA 73-57

I. OBJECTIVE

The objective of this study was to evaluate the test compound for genetic activity in microbial assays with and without the addition of mammalian metabolic activation preparations.

II. MATERIALS

A. Test Compound

1. Date Received: August, 1974
2. Description: White waxy chunks

B. Indicator Microorganisms

The following strains of indicator microorganisms were used in the evaluation:

Yeast Strain: Saccharomyces cerevisiae, strain D4

Bacteria Strains: Salmonella typhimurium, strains: TA-1535  
TA-1537  
TA-1538

C. Reaction Mixture

The following reaction mixture was employed in the activation tests:

<u>Component</u>	<u>Final Concentration/ml</u>
1. TPN (sodium salt)	6.0 $\mu$ M
2. Isocitric acid	49.0 $\mu$ M
3. Tris buffer, pH 7.4	28.0 $\mu$ M
4. $MgCl_2$	1.7 $\mu$ M
5. Tissue homogenate fraction	72.0 mg



BIONETICS

#### D. Tissue Homogenates and Supernatants

The tissue homogenates and 9,000 x g supernatants were prepared from tissues of the following mammalian species: Mouse-ICR random bred adult males; rat-Sprague-Dawley adult males; and primate-Macaca mulatta adult males.

#### E. Positive Control Compounds

Table 1 lists chemicals for positive controls in the direct and activation assays.

TABLE 1  
POSITIVE CONTROLS USED IN DIRECT AND ACTIVATION ASSAYS

<u>Assay</u>	<u>Chemical</u> <sup>a</sup>	<u>Solvent</u>	<u>Probable Mutagenic Specificity</u>
Nonactivation	Ethyl methanesulfonate	Water or saline	BPS <sup>b</sup>
	2-Nitrofluorene	Dimethylsulfoxide <sup>c</sup>	FS <sup>b</sup>
	Quinacrine mustard	Water or saline	FS <sup>b</sup>
Activation	Dimethylnitrosamine	Water or saline	BPS <sup>b</sup>
	2-Acetylaminofluorene	Dimethylsulfoxide <sup>c</sup>	FS <sup>b</sup>

<sup>a</sup> Concentrations given in the Results Section

<sup>b</sup> BPS = base-pair substitution; FS = frameshift

<sup>c</sup> Previously shown to be non-mutagenic

### III. METHODS

#### A. Toxicity

The solubility, toxicity and doses for all chemicals were determined prior to screening.

Each chemical was tested for survival against the specific indicator strains over a range of doses to determine the 50% survival dose. Bacteria were tested in phosphate buffer, pH 7.4, for one hour at 37°C on a shaker. Yeasts were tested in phosphate buffer, pH 7.4, for four hours at 30°C on a shaker. The 50% survival curve and the 1/4 and 1/2 50% doses calculated.

If no toxicity was obtained for a chemical with a given strain, then a maximum dose of 5% (w/v) was used against the strain.

Unless otherwise specified, the doses calculated for the tests in buffer were applied to the activation tests. The solubility of the test chemical under treatment conditions is stated in the Results Section.



**BIONETICS**

Litton

## B. Plate Tests

In the nonactivation procedure, approximately  $10^9$  cells of a log-phase culture of the bacterial indicator strains were spread over the surface of a minimal plate, and a measured amount of the test chemical was placed in the center of the test plate. In activation tests, the test chemical was added to the cells, and an aliquot of the mixture was spread on the surface of the test plate. The reaction mixture (0.1 ml) plus tissue extract was then spotted on the surface of the plate. Positive and solvent controls were included. All plates were incubated at 37°C for four days and then scored. Each compound (test, positive control and solvent control) was done in duplicate. Concentrations of the positive control compounds are listed in the Results Section.

## C. Suspension Tests

### 1. Nonactivation

Log-phase bacteria and stationary-phase yeast cultures of the indicator organisms were grown in complete broth, washed and resuspended in 0.9% saline to densities of  $1 \times 10^9$  cells/ml and  $5 \times 10^7$  cells/ml, respectively. This constituted the working stock for tests of a group of test chemicals and their respective controls. Tests were conducted in plastic tissue culture plates. Cells plus appropriate volume(s) of the test chemical were added to the wells to give a final volume of 1.5 ml. The solvent replaced the test chemical in the negative controls. Treatment was at 30°C for four hours for yeast tests and at 37°C for one hour for bacterial tests. All flasks were shaken during treatment. Following treatment, the plates were set on ice. Aliquots of cells were removed, diluted in sterile saline (4°C) and plated on the appropriate complete media. Undiluted samples from flasks containing the bacteria were plated on minimal selective medium in reversion experiments. Samples from a  $10^{-1}$  dilution of treated cells were plated on the selected media for enumeration of gene conversion with strain D4. Bacterial plates were scored after incubation for 48 hours at 37°C. The yeast plates were incubated at 30°C for 3-5 days before scoring.

### 2. Activation

Bacteria and yeast cells were grown and prepared as described in the nonactivation tests. Measured amounts of the test and control chemicals plus 0.25 ml of the stock-cell suspension were added to wells of the Linbro plate containing the appropriate tissue fraction and reaction mixture. All flasks (bacteria and yeast) were incubated at 37°C in an oxygen atmosphere with shaking. The treatment times as well as the dilutions, plating procedures and scoring of the plates were the same as described for nonactivation tests.



BIONETICS

D. Preparation of Tissue Homogenates and 9,000 x g Cell Fractions

Male animals (sufficient to provide the necessary quantities of tissues) were killed by cranial blow, decapitated and bled. Organs were immediately dissected from the animal using aseptic techniques and placed in ice-cold 0.25 M sucrose buffered with Tris at pH of 7.4. Upon collection of the desired quantity of organs, they were washed twice with fresh buffered sucrose and completely homogenized with a motor-driven homogenizing unit at 4°C. The whole organ homogenate obtained from this step was divided into two samples. One sample was frozen at -80°C and the other was centrifuged for 20 minutes at 9,000 x g in a refrigerated centrifuge. The supernatant from the centrifuged sample was retained and frozen at -80°C. These two frozen samples were used for the activation studies.

E. Data Recording and Reporting

Following the specified incubation periods all population plates were scored by an automatic colony counter and the results from each plate of a set were recorded, in ink, on data processing forms. All minimal or other types of selective media plates were hand scored and the results recorded along with the respective population data. Other relevant experimental data were recorded on experimental definition forms. For bacteria strains the number of colonies recorded from either the population or selective plates represents that number in 1 ml of test suspension plated. The numbers recorded for the yeast strain D4 represent the number in 0.5 ml of test suspension plated. The data were then processed and printed from a computer program.



IV. RESULTS SECTION

A. Solubility Properties of the Test Compound

1. Name or code designation of the test compound: 001323393  
Propylene Glycol Monostearate
2. Test solvent: DMSO
3. Solubility of the test compound under treatment conditions:  
Insoluble under treatment conditions.
4. Additional comments: White waxy chunks

B. Toxicity and Dosage Determinations for the Test Compound

1. Test date for toxicity determination: February 11, 1975
2. The 50% survival level was determined for bacteria and yeast indicator organisms by conducting survival curves with the test compound at the following concentrations:

Percent Concentration (w/v or v/v)

5.0  
0.5  
0.05  
0.005  
0.0005

3. Concentrations of the test compound used in the mutagenicity tests:

<u>Dose</u>	<u>Percent Concentration</u>	
	<u>Bacteria</u>	<u>Yeast</u>
1/4 50% Survival	2.5	0.5
1/2 50% Survival	5.0	1.0
50% Survival	10.0	2.0
Plate Tests	5.0	--



BIONETICS

# V. SUMMARY OF TEST RESULTS

## Plate Tests

A. Name or code designation of the test compound: 001323393

B. Test date: March 29, 1975

C. Concentration of the test compound: 5.0%

Test	Species	Tissue	TA-1535		TA-1537		TA-1538	
			1	2	1	2	1	2
1. <u>Nonactivation</u>								
Solvent Control	---	---	11	20	4	5	15	11
Positive Control <sup>a</sup>	---	---	>10 <sup>5</sup>	>10 <sup>5</sup>	193	207	145	134
Test Compound	---	---	2	5	3	0	10	5
2. <u>Activation</u>								
Negative Control	---	---	7	10	6	3	7	12
Solvent Control	---	---	20	24	5	9	15	14
Reaction Mixture Control	---	---	23	20	7	8	18	16
Positive Control <sup>b</sup>	Mouse	Liver	>10 <sup>3</sup>	>10 <sup>3</sup>	39	34	343	357
Positive Control		Lung	12	8	2	1	11	16
Positive Control		Testes	16	17	3	8	7	11
Positive Control	Rat	Liver	>10 <sup>3</sup>	>10 <sup>3</sup>	89	88	347	341
Positive Control		Lung	14	7	2	3	14	18
Positive Control		Testes	16	13	5	7	10	13
Positive Control	Monkey	Liver	273	350	30	33	123	119
Positive Control		Lung	8	8	2	2	13	14
Positive Control		Testes	15	12	3	6	8	11
Test Compound	Mouse	Liver	20	10	2	3	5	6
Test Compound		Lung	10	15	1	1	4	11
Test Compound		Testes	28	34	3	4	13	7
Test Compound	Rat	Liver	13	6	0	2	8	9
Test Compound		Lung	0	3	1	2	8	11
Test Compound		Testes	7	11	1	1	7	3
Test Compound	Monkey	Liver	13	6	3	4	9	10
Test Compound		Lung	1	3	1	1	1	7
Test Compound		Testes	7	11	4	5	4	2

a TA-1535 EMS 10 µl/plate  
TA-1537 QM 20 µg/plate  
TA-1538 NF 100 µg/plate

b TA-1535 DMNA 50 µM/plate  
TA-1537 AAF 100 µg/plate  
TA-1538 AAF 100 µg/plate



BIONETICS

## DATA TABLE TERMS AND ABBREVIATIONS

ABBREVIATION OR TERM	DEFINITION OR EXPLANATION
COMPOUND	Client designated compound number appears in this column.
TEST CODES	<p> NAN = Nonactivation: Solvent Control  NAP = Nonactivation: Positive Control  NA1 = Nonactivation: Test Compound Dose 1  NA2, etc. = Reflects the other dose level(s) </p> <p> A+C = Negative Chemical Control  A-C = Activation: Solvent Control  ACP = Activation: Positive Control  ACT = Activation: Test Compound  A+T = Activation: Tissue Control </p> <p> LI = Liver Tissue Activation Fraction  LU = Lung Tissue Activation Fraction  KI = Kidney Tissue Activation Fraction  TE = Testes Tissue Activation Fraction  1,2, etc. = Dose Levels </p>
CONCENTRATION	<p>All test compound dose levels are expressed as a whole number followed by an exponent (negative) identified by the appropriate units.</p> <p>Example: 0025-2PCT = 0.25 percent concentration</p>
POPU	Total number of viable cells in the plating sample raised to some exponent printed directly below the abbreviation (i.e., EP + 6 = $\times 10^6$ ).
MUT 1	Total number of mutants or convertants obtained from the sample plated raised to some exponent printed directly below the abbreviation (i.e., EP + 0 = $\times 10^0$ ). For strain D4, MUT 1 represents the number of ADE+ convertants.
MUT 2	Only used for strain D4 and represents the number of TRY+ convertants in the plated sample.
FREQ 1	The calculated mutation or gene conversion frequency times the negative exponent written directly below. For strain D4, FREQ 1 represents the ADE+ value.
FREQ 2	Only used for strain D4 and represents the TRY+ conversion frequency.
CONTAM	Presence of contamination on any plates.



**BIONETICS**

# DATA TABLE TERMS AND ABBREVIATIONS (continued)

ABBREVIATION OR TERM	DEFINITION OR EXPLANATION
AAF	2-Acetylaminofluorene
DMSO	Dimethylsulfoxide
DMN	Dimethylnitrosamine
EMS	Ethyl Methanesulfonate
QM	Quinacrine Mustard
NF	Nitrofluorene
SPECIES	Animal Strains
SPRDAW	Sprague Dawley Rats
ICRFLO	Flow ICR Random Bred Mice
RHESUS	Rhesus Monkey ( <u>Macaca mulatta</u> )
MIXEDB	Dog, Mixed Breed
NEWZEA	New Zealand White Rabbit



BIONETICS

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 05/15/75

SPECIES

COMPOUND 001323393

TEST	ORG	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5
NAN		10.15	2.10	9.02	1.58	1.69
NAP		273.70	225.89	145.97	113.25	60.11
NA1		13.04	1.63	5.76	1.61	0.64
NA2		13.12	1.00	10.79	0.22	1.56



BIONETICS

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 05/15/75

SPECIES ICRFLO COMPOUND 000094133

TEST	ORG	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	TA1538 HIS EX-8	TA1538 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5
ACT	A+C	5.99	2.10	11.20			16.01	4.11
ACT	A+T	12.45	2.10	10.46			15.24	3.26
ACT	A-C	6.65	2.91	10.54	3.19	7.30	19.85	3.33
ACT	PLI	1168.86	10.07	37.43			20.62	4.92
ACT	PLU	8.06	2.19	12.57			39.08	3.22
ACT	PTE	9.32	2.86	12.54			23.53	3.29
ACT	LI1	21.14	2.54	42.95	5.75		14.64	3.35
ACT	LI2	12.75	3.23	29.10	4.88		11.19	3.23
ACT	LU1	24.54	1.85	13.88			12.88	3.22
ACT	LU2	10.11	3.05	11.63			15.21	3.69
ACT	TE1	16.38	1.56	30.71		7.89	15.52	5.30
ACT	TE2	14.26	2.31	10.53			28.25	4.56



BIONETICS

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 05/15/75

SPECIES SPRDAW COMPOUND 001323393

TEST	ORG	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5
ACT	A+C	17.47	0.63	5.39	0.58	0.39
ACT	A+T	11.03	1.23	10.55	2.35	2.75
ACT	A-C	11.62	0.58	5.36	0.72	0.18
ACT	PLI	1500.00	7.28	59.37	8.75	10.22
ACT	PLU	18.29	0.84	7.31	3.40	1.39
ACT	PTE	22.47	0.33	8.13	3.38	1.93
ACT	LI1	10.77	1.14	5.90	1.14	4.71
ACT	LI2	10.63	1.09	10.10	2.23	5.01
ACT	LU1	6.43	0.67	11.71	1.20	1.32
ACT	LU2	6.60	1.13	5.52	0.95	0.82
ACT	TE1	5.06	0.84	8.56	2.32	1.83
ACT	TE2	6.89	0.58	12.24	0.71	2.14



BIONETICS

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 05/15/75

SPECIES RHESUS COMPOUND 001323393

TEST	ORG	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5
ACT	A+C	7.43	7.44	4.49	10.40	1.65
ACT	A+T	14.05	11.84	4.09	15.69	2.55
ACT	A-C	7.01	7.04	5.55	14.76	2.24
ACT	PLI	1352.79	19.31	24.13	14.99	2.71
ACT	PLU	4.62	6.35	2.77	12.58	2.35
ACT	PTE	8.16	8.79	6.29	20.07	2.79
ACT	LI1	8.82	6.00	3.43	11.68	0.60
ACT	LI2	6.79	7.25	2.85	10.48	1.31
ACT	LU1	5.15	6.51	0.56	14.72	1.87
ACT	LU2	5.79	8.76	2.00	10.74	2.73
ACT	TE1	5.67	6.33	2.69	12.26	0.94
ACT	TE2	8.43	5.68	4.41	11.87	3.34



BIONETICS

## VI. INTERPRETATION OF RESULTS AND CONCLUSIONS

Compound FDA 73-57, Propylene Glycol Monostearate, was evaluated for genetic activity in a series of in vitro microbial assays with and without metabolic activation. The following results were obtained:

### A. Salmonella typhimurium

#### 1. Plate Tests

At a concentration of 5.0%, this compound was not mutagenic in direct or activation plate tests.

#### 2. Nonactivation suspension tests

The results of these tests were negative.

#### 3. Activation suspension tests

The results of these tests were negative. The LI1, LI2 and TE1 tests with TA-1538 using mouse tissues showed increased reversion frequencies in the initial runs. Repeat tests were all negative.

### B. Saccharomyces cerevisiae

#### 1. Nonactivation suspension tests

The results of these tests were negative.


#### 2. Activation suspension tests

The results of these tests were negative.

### C. Conclusions

The compound Propylene Glycol Monostearate did not exhibit genetic activity in any of the in vitro microbial assays employed in this evaluation.

Submitted by:



David Brusick, Ph.D.  
Director of Genetics



BIONETICS

APPENDIX  
Tabulation of Data



Litton

BIONETICS



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104			PROJECT 02468				
EXPERIMENT 505803		DETECTOR TA1535	SPECIES		DATE - 05/15/75		
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SALINE	1340	0136	10.15	0
	NAP		EMS 0.002 %	1327	3632	273.70	0
001323393	NA1		0005-0 PCT.	0675	0088	13.04	2
001323393	NA2		0025-1 PCT.	0686	0090	13.12	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 22374-2104		PROJECT 02468		DATE - 05/15/75	
EXPERIMENT 508301		DETECTOR TA1537		SPECIES			
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SALINE	0713	0015	2.10	0
	NAP		QM 1.0 UG/ML	0421	0951	225.89	0
001323393	NA1		0005-0 PCT.	0922	0015	1.63	0
001323393	NA2		0025-1 PCT.	1103	0011	1.00	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 22374-2104		PROJECT 02468			
EXPERIMENT 505802		DETECTOR TA1538		SPECIES			
				DATE - 05/15/75			
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		DMSO	0599	0054	9.02	0
	NAP		NF 125 UG-ML	0546	0797	145.97	0
001323393	NA1		0005-0 PCT.	0347	0020	5.76	0
001323393	NA2		0025-1 PCT.	0445	0048	10.79	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 22374-2104		PROJECT 02468					
EXPERIMENT 505804		DETECTOR 0000D4		SPECIES		DATE - 05/15/75			
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	NAN		SALINE	0947	0015	0016	1.58	1.69	0
	NAP		EMS 1.0 %	0702	0795	0422	113.25	60.11	7
001323393	NA1		0001-0 PCT.	0311	0005	0002	1.61	0.64	1
001323393	NA2		0005-1 PCT.	0448	0001	0007	0.22	1.56	1



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 22374-2104		PROJECT 02468			
EXPERIMENT 506301		DETECTOR TA1535		SPECIES ICRFLO		DATE - 05/15/75	
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 50 UM/ML	0734	0044	5.99	0
	A+T		***NO MATCH***	0819	0102	12.45	0
	A-C		SALINE	0917	0061	6.65	0
	ACP	LI	DMN 50 UM/ML	0456	5330	1168.86	1
	ACP	LU	DMN 50 UM/ML	0608	0049	8.06	0
	ACP	TE	DMN 50 UM/ML	0590	0055	9.32	0
001323393	ACT	LI1	0005-0 PCT.	0785	0072	9.17	2
001323393	ACT	LI2	0025-1 PCT.	0721	0070	9.71	2
001323393	ACT	LU1	0005-0 PCT.	0682	0063	9.24	0
001323393	ACT	LU2	0025-1 PCT.	0720	0078	10.83	2
001323393	ACT	TE1	0005-0 PCT.	0802	0080	9.98	2
001323393	ACT	TE2	0025-1 PCT.	0890	0072	8.09	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468  
EXPERIMENT 505901 DETECTOR TA1537 SPECIES ICRFLO DATE - 05/15/75

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AAF 800 UG/ML	1476	0031	2.10	0
	A+T		***NO MATCH***	1524	0032	2.10	0
	A-C		DMSO	1445	0042	2.91	0
	ACP	LI	AAF 800 UG/ML	1489	0150	10.07	0
	ACP	LU	AAF 800 UG/ML	1463	0032	2.19	0
	ACP	TE	AAF 800 UG/ML	1293	0037	2.86	0
001323393	ACT	LI1	0005-0 PCT.	1238	0033	2.67	0
001323393	ACT	LI2	0025-1 PCT.	1280	0033	2.58	0
001323393	ACT	LU1	0005-0 PCT.	1314	0014	1.07	2
001323393	ACT	LU2	0025-1 PCT.	1341	0035	2.61	0
001323393	ACT	TE1	0005-0 PCT.	1282	0043	3.35	0
001323393	ACT	TE2	0025-1 PCT.	1409	0031	2.20	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468  
EXPERIMENT 506401 DETECTOR TA1538 SPECIES ICRFLO DATE - 05/15/75

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AAF 800 UG/ML	0598	0067	11.20	0
	A+T		***NO MATCH***	0841	0088	10.46	0
	A-C		DMSO	0446	0047	10.54	0
	ACP	LI	AAF 800 UG/ML	0505	0189	37.43	0
	ACP	LU	AAF 800 UG/ML	0565	0071	12.57	2
	ACP	TE	AAF 800 UG/ML	0606	0076	12.54	0
001323393	ACT	LI1	0005-0 PCT.	0391	0090	23.02	2
001323393	ACT	LI2	0025-1 PCT.	0420	0080	19.05	2
001323393	ACT	LU1	0005-0 PCT.	0429	0077	17.95	2
001323393	ACT	LU2	0025-1 PCT.	0594	0038	6.40	2
001323393	ACT	TE1	0005-0 PCT.	0578	0075	12.98	2
001323393	ACT	TE2	0025-1 PCT.	0569	0066	11.60	2



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 22374-2104		PROJECT 02468					
EXPERIMENT 510401		DETECTOR 0000D4		SPECIES ICRFLO			DATE - 05/15/75		
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	0706	0113	0029	16.01	4.11	0
	A+T		***NO MATCH***	1319	0201	0043	15.24	3.26	6
	A-C		SALINE	0660	0131	0022	19.85	3.33	2
	ACP	LI	DMN 90 UM/ML	0325	0067	0016	20.62	4.92	6
	ACP	LU	DMN 90 UM/ML	0870	0340	0028	39.08	3.22	2
	ACP	TE	DMN 90 UM/ML	0850	0200	0028	23.53	3.29	4
001323393	ACT	LI1	0001-0 PCT.	0371	0064	0017	17.25	4.58	2
001323393	ACT	LI2	0005-1 PCT.	0450	0138	0017	30.67	3.78	6
001323393	ACT	LU1	0001-0 PCT.	0355	0061	0009	17.18	2.54	2
001323393	ACT	LU2	0005-1 PCT.	0482	0075	0011	15.56	2.28	0
001323393	ACT	TE1	0001-0 PCT.	0421	0062	0015	14.73	3.56	7
001323393	ACT	TE2	0005-1 PCT.	0299	0064	0022	21.40	7.36	6



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104

PROJECT 02468

EXPERIMENT 506501

DETECTOR TA1535

SPECIES SPRDAW

DATE - 05/15/75

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 50 UM/ML	0435	0076	17.47	0
	A+T		***NO MATCH***	0571	0063	11.03	0
	A-C		SALINE	0697	0081	11.62	0
	ACP	LI	DMN 50 UM/ML	0388	5820	1500.00	0
	ACP	LU	DMN 50 UM/ML	0410	0075	18.29	0
	ACP	TE	DMN 50 UM/ML	0356	0080	22.47	2
001323393	ACT	LI1	0005-0 PCT.	0622	0067	10.77	0
001323393	ACT	LI2	0025-1 PCT.	0734	0078	10.63	0
001323393	ACT	LU1	0005-0 PCT.	0622	0040	6.43	0
001323393	ACT	LU2	0025-1 PCT.	0591	0039	6.60	0
001323393	ACT	TE1	0005-0 PCT.	1008	0051	5.06	2
001323393	ACT	TE2	0025-1 PCT.	0682	0047	6.89	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104

PROJECT 02468

EXPERIMENT 507001

DETECTOR TA1537

SPECIES SPRDAW

DATE - 05/15/75

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AAF 800 UG/ML	1906	0012	0.63	0
	A+T		***NO MATCH***	2198	0027	1.23	0
	A-C		DMSO	1900	0011	0.58	0
	ACP	LI	AAF 800 UG/ML	1594	0116	7.28	0
	ACP	LU	AAF 800 UG/ML	1657	0014	0.84	2
	ACP	TE	AAF 800 UG/ML	1841	0006	0.33	2
001323393	ACT	LI1	0005-0 PCT.	2010	0023	1.14	0
001323393	ACT	LI2	0025-1 PCT.	1918	0021	1.09	0
001323393	ACT	LU1	0005-0 PCT.	2075	0014	0.67	2
001323393	ACT	LU2	0025-1 PCT.	1944	0022	1.13	2
001323393	ACT	TE1	0005-0 PCT.	1897	0016	0.84	0
001323393	ACT	TE2	0025-1 PCT.	2062	0012	0.58	2



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468  
EXPERIMENT 507901 DETECTOR TA1538 SPECIES SPRDAW DATE - 05/15/75

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AAF 800 UG/ML	0445	0024	5.39	0
	A+T		***NO MATCH***	0275	0029	10.55	2
	A-C		DMSO	0392	0021	5.36	0
	ACP	LI	AAF 800 UG/ML	0507	0301	59.37	0
	ACP	LU	AAF 800 UG/ML	0588	0043	7.31	0
	ACP	TE	AAF 800 UG/ML	0541	0044	8.13	0
001323393	ACT	LI1	0005-0 PCT.	0441	0026	5.90	2
001323393	ACT	LI2	0025-1 PCT.	0386	0039	10.10	0
001323393	ACT	LU1	0005-0 PCT.	0350	0041	11.71	1
001323393	ACT	LU2	0025-1 PCT.	0417	0023	5.52	0
001323393	ACT	TE1	0005-0 PCT.	0374	0032	8.56	0
001323393	ACT	TE2	0025-1 PCT.	0433	0053	12.24	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104			PROJECT 02468						
EXPERIMENT 506601			DETECTOR 0000D4	SPECIES SPRDAW			DATE - 05/15/75		
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	1037	0006	0004	0.58	0.39	4
	A+T		***NO MATCH***	1020	0024	0028	2.35	2.75	4
	A-C		SALINE	1104	0008	0002	0.72	0.18	4
	ACP	LI	DMN 90 UM/ML	0949	0083	0097	8.75	10.22	4
	ACP	LU	DMN 90 UM/ML	0794	0027	0011	3.40	1.39	6
	ACP	TE	DMN 90 UM/ML	1035	0035	0020	3.38	1.93	4
001323393	ACT	LI1	0001-0 PCT.	0700	0008	0033	1.14	4.71	7
001323393	ACT	LI2	0005-1 PCT.	0719	0016	0036	2.23	5.01	7
001323393	ACT	LU1	0001-0 PCT.	0835	0010	0011	1.20	1.32	7
001323393	ACT	LU2	0005-1 PCT.	0735	0007	0006	0.95	0.82	7
001323393	ACT	TE1	0001-0 PCT.	0818	0019	0015	2.32	1.83	7
001323393	ACT	TE2	0005-1 PCT.	0842	0006	0018	0.71	2.14	7



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468  
EXPERIMENT 507201 DETECTOR TA1535 SPECIES RHESUS DATE - 05/15/75

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 50 UM/ML	0888	0066	7.43	2
	A+T		***NO MATCH***	0541	0076	14.05	0
	A-C		SALINE	0913	0064	7.01	0
	ACP	LI	DMN 50 UM/ML	0502	6791	1352.79	0
	ACP	LU	DMN 50 UM/ML	0823	0038	4.62	0
	ACP	TE	DMN 50 UM/ML	0625	0051	8.16	0
001323393	ACT	LI1	0005-0 PCT.	0771	0068	8.82	2
001323393	ACT	LI2	0025-1 PCT.	0854	0058	6.79	2
001323393	ACT	LU1	0005-0 PCT.	0854	0044	5.15	0
001323393	ACT	LU2	0025-1 PCT.	0984	0057	5.79	2
001323393	ACT	TE1	0005-0 PCT.	0653	0037	5.67	2
001323393	ACT	TE2	0025-1 PCT.	0581	0049	8.43	2



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104

PROJECT 02468

EXPERIMENT 511401 DETECTOR TA1537 SPECIES RHESUS DATE - 05/15/75

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AAF 800 UG/ML	0847	0063	7.44	2
	A+T		***NO MATCH***	0515	0061	11.84	0
	A-C		DMSO	0710	0050	7.04	0
	ACP	LI	AAF 800 UG/ML	0844	0163	19.31	0
	ACP	LU	AAF 800 UG/ML	0914	0058	6.35	0
	ACP	TE	AAF 800 UG/ML	0842	0074	8.79	0
001323393	ACT	LI1	0005-0 PCT.	0300	0018	6.00	0
001323393	ACT	LI2	0025-1 PCT.	0621	0045	7.25	2
001323393	ACT	LU1	0005-0 PCT.	0507	0033	6.51	0
001323393	ACT	LU2	0025-1 PCT.	0502	0044	8.76	0
001323393	ACT	TE1	0005-0 PCT.	0600	0038	6.33	0
001323393	ACT	TE2	0025-1 PCT.	0740	0042	5.68	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468  
EXPERIMENT 507601 DETECTOR TA1538 SPECIES RHESUS DATE - 05/15/75

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AAF 800 UG/ML	0802	0036	4.49	0
	A+T		***NO MATCH***	0464	0019	4.09	0
	A-C		DMSO	0721	0040	5.55	0
	ACP	LI	AAF 800 UG/ML	0601	0145	24.13	2
	ACP	LU	AAF 800 UG/ML	0649	0018	2.77	0
	ACP	TE	AAF 800 UG/ML	0572	0036	6.29	0
001323393	ACT	LI1	0005-0 PCT.	0408	0014	3.43	0
001323393	ACT	LI2	0025-1 PCT.	0421	0012	2.85	0
001323393	ACT	LU1	0005-0 PCT.	0536	0003	0.56	0
001323393	ACT	LU2	0025-1 PCT.	0500	0010	2.00	0
001323393	ACT	TE1	0005-0 PCT.	0631	0017	2.69	0
001323393	ACT	TE2	0025-1 PCT.	0522	0023	4.41	0



LITTON  
BIONETICS

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM  
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104				PROJECT 02468					
EXPERIMENT 510501		DETECTOR 0000D4		SPECIES RHESUS		DATE - 05/15/75			
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	0423	0044	0007	10.40	1.65	0
	A+T		***NO MATCH***	0548	0086	0014	15.69	2.55	0
	A-C		SALINE	0759	0112	0017	14.76	2.24	0
	ACP	LI	DMN 90 UM/ML	0774	0116	0021	14.99	2.71	0
	ACP	LU	DMN 90 UM/ML	0469	0059	0011	12.58	2.35	0
	ACP	TE	DMN 90 UM/ML	0538	0108	0015	20.07	2.79	0
001323393	ACT	LI1	0001-0 PCT.	0334	0039	0002	11.68	0.60	0
001323393	ACT	LI2	0005-1 PCT.	0458	0048	0006	10.48	1.31	0
001323393	ACT	LU1	0001-0 PCT.	0428	0063	0008	14.72	1.87	0
001323393	ACT	LU2	0005-1 PCT.	0512	0055	0014	10.74	2.73	0
001323393	ACT	TE1	0001-0 PCT.	0530	0065	0005	12.26	0.94	0
001323393	ACT	TE2	0005-1 PCT.	0539	0064	0018	11.87	3.34	0